Drugs / S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00211926 | Dec 2004 → Jun 2006 | periprosthetic joint infection, staphylococcus aureus infection | Nabi Biopharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00211913 | Jun 2004 → Oct 2005 | cardiovascular disorder, staphylococcus aureus infection | Nabi Biopharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00211913 ↗ |
| Known as | StaphVAX | “StaphVAX® is a vaccine to prevent these infections, which conjugates the purified capsular polysaccharides of S. aureus to a carrier protein.” NCT00211926 ↗ |